AI Article Synopsis
- Pidotimod is a synthetic dipeptide that modifies both innate and adaptive immunity by acting on Toll-like receptors and immunocompetent cells, influencing immunoglobulin production.
- It has been shown to effectively prevent respiratory infections, particularly in children who experience frequent infections, and can be used as an add-on treatment for infections.
- There is also evidence suggesting that pidotimod may benefit children with asthma and allergic diseases due to its role in preventing respiratory infections, with studies indicating it is safe and well-tolerated.
Article Abstract
Pidotimod is a synthetic dipeptide that exerts immunomodulatory activity, modifying innate and adaptive immunity. Pidotimod firstly acts on Toll-like receptors, then on antigen-presenting cells and other immunocompetent cells. Pidotimod also affects immunoglobulin production and their switching. Evidence shows that pidotimod effectively and safely prevents respiratory infections, mainly in children with recurrent and frequent infectious episodes. In addition, pidotimod may be helpful as an add-on strategy in managing children with infections. Finally, there is evidence that pidotimod, thanks to its immunomodulatory activity and preventing respiratory infections (the main trigger for asthma exacerbation), may be beneficial in managing subjects with asthma and allergic diseases. The present review presents and discusses the most recent studies conducted in children with asthma, allergic rhinitis, recurrent respiratory infections and acute infections. Lastly, pidotimod is safe and well-tolerated in children.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5826/mrm.2024.986 | DOI Listing |
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661399 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!